Physician profile
Jason K Ho
NPI 1578676334
$2,916.41
in general payments reported to CMS, 2019-2025
23 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $432 · 2021: $430 · 2022: $316 · 2023: $432 · 2024: $579 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.37 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $598.65 | 2019-2024 | |
| Glaxosmithkline, LLC. | $306.42 | 2020-2025 | Ojjaara |
| Taiho Oncology, INC. | $234.61 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $223.68 | 2020-2025 | Opdualag, Opdivo |
| Lilly USA, LLC | $197.55 | 2020-2025 | Retevmo, Jaypirca, Verzenio |
| Daiichi Sankyo INC. | $157.65 | 2019-2022 | |
| Janssen Biotech, INC. | $139.64 | 2019-2025 | Rybrevant |
| Pfizer INC. | $139.58 | 2019-2025 | |
| Astellas Pharma US INC | $124.65 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $118.57 | 2024 | Tremfya |
| Eisai INC. | $114.63 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $113.94 | 2021 | |
| Kyowa Kirin, INC. | $77.38 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.09 | 2022-2025 | Fruzaqla |
| Abbvie INC. | $52.68 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $47.59 | 2023-2024 | Elahere, Elahere |
| Emd Serono, INC. | $46.97 | 2025 | |
| Cook Medical LLC | $29.04 | 2022 | |
| Exelixis INC. | $28.26 | 2024 | Cabometyx |
| Immunocore Limited | $27.96 | 2024 | Kimmtrak |
| Immunomedics, INC. | $24.59 | 2020 | |
| Puma Biotechnology, INC. | $21.42 | 2020 | |
| Mirati Therapeutics, INC. | $19.86 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.